And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. This time around, though, we can ponder a much longer stretch, since we will be taking a break until Jan. 2. As for our agenda, it remains in flux. We hope to spend time with our short people, especially helping our shortest acclimate to the driving machine; catch up on our reading; visit the Pharmalot ancestors; and, of course, take some naps. And what about you? This is a holiday season for so many, of course, so perhaps this would be a nice time to catch up with someone special or maybe take stock. You could also take time to explore the world, far or near. Or place a bet on whether a certain wall gets built. Well, whatever you do, have a grand time. But be safe. Enjoy, and see you next year …

Get set for drug prices to rise next month, STAT tells us. Roughly two-thirds of medicines that are closely tracked by payers due to cost are expected to rise between 7 percent and 9 percent next month, according to Bernstein analyst Ronny Gal. And wholesale prices for drugs that are administered by physicians should increase by about 3 percent. Overall, “the breadth of the increases is about 20 percent higher than previous years,” he wrote in an investor note after surveying payers.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • Hmmm …. “ordered Johnson and Johnson (JNJ) not to use talc raw material from its Mulund plant in Mumbai and Baddi unit in Himachal Pradesh” ….. shades of Fort Washington / McNeil 10 years later? Hopefully not …..

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy